Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS.

Open source

DOI: 10.1136/jitc-2021-003776
Published: 2022-02-01
Container: J Immunother Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-003776,
  title = {Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.},
  author = {Schöffski P and  Tan DSW and  Martín M and  Ochoa-de-Olza M and  Sarantopoulos J and  Carvajal RD and  Kyi C and  Esaki T and  Prawira A and  Akerley W and  De Braud F and  Hui R and  Zhang T and  Soo RA and  Maur M and  Weickhardt A and  Krauss J and  Deschler-Baier B and  Lau A and  Samant TS and  Longmire T and  Chowdhury NR and  Sabatos-Peyton CA and  Patel N and  Ramesh R and  Hu T and  Carion A and  Gusenleitner D and  Yerramilli-Rao P and  Askoxylakis V and  Kwak EL and  Hong DS.},
  year = {2022},
  journal = {J Immunother Cancer},
  doi = {10.1136/jitc-2021-003776},
  url = {https://doi.org/10.1136/jitc-2021-003776}
}

RIS

TY  - JOUR
TI  - Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
AU  - Schöffski P
AU  -  Tan DSW
AU  -  Martín M
AU  -  Ochoa-de-Olza M
AU  -  Sarantopoulos J
AU  -  Carvajal RD
AU  -  Kyi C
AU  -  Esaki T
AU  -  Prawira A
AU  -  Akerley W
AU  -  De Braud F
AU  -  Hui R
AU  -  Zhang T
AU  -  Soo RA
AU  -  Maur M
AU  -  Weickhardt A
AU  -  Krauss J
AU  -  Deschler-Baier B
AU  -  Lau A
AU  -  Samant TS
AU  -  Longmire T
AU  -  Chowdhury NR
AU  -  Sabatos-Peyton CA
AU  -  Patel N
AU  -  Ramesh R
AU  -  Hu T
AU  -  Carion A
AU  -  Gusenleitner D
AU  -  Yerramilli-Rao P
AU  -  Askoxylakis V
AU  -  Kwak EL
AU  -  Hong DS.
PY  - 2022
JO  - J Immunother Cancer
DO  - 10.1136/jitc-2021-003776
UR  - https://doi.org/10.1136/jitc-2021-003776
ER  -

APA

P, S., DSW, T., M, M., M, O., J, S., RD, C., C, K., T, E., A, P., W, A., F, D. B., R, H., T, Z., RA, S., M, M., A, W., J, K., B, D., A, L., TS, S., T, L., NR, C., CA, S., N, P., R, R., T, H., A, C., D, G., P, Y., V, A., EL, K., & DS., H. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-003776

Source records

europe-pmc · retrieved 2026-09-25T06:07:25.964Z
doaj · retrieved 2026-09-25T06:07:25.944Z